Abstract
The topical application of therapeutic agent has shown promising efficacy in the treatment of skin disorders. The siRNA based therapies have been used for treatment of various disorders including skin diseases. The topical delivery of siRNA based therapies has opened new perspectives for the treatment of skin disorders. The use of siRNA is limited due to the rapid degradation and poor cellular uptake. Also, the stratum corneum, the top layer of skin is the major barrier for the delivery of topical agents. There is unmet need for efficient topical formulation that will deliver the siRNA to the site of action and also overcome the associated siRNA delivery limitations. The topical delivery of siRNA has been achieved using viral or nonviral methods, and the combination of non-viral methods with an active permeation method such as iontophoresis, sonophoresis or microneedles for the treatment of skin disorders. These delivery approaches have been tested in a preclinical setup and few cases the results have shown promise for clinical trials. This review provides an update on the advances in the non-viral delivery approaches for siRNA delivery for skin disorders and use of various delivery approaches for efficient delivery at the disease site.
Keywords: siRNA, skin disorders, topical, nanoparticle.
Current Pharmaceutical Design
Title:Progress in Topical siRNA Delivery Approaches for Skin Disorders
Volume: 21 Issue: 31
Author(s): Mohammed Aldawsari, Mahavir B. Chougule and R. Jayachandra Babu
Affiliation:
Keywords: siRNA, skin disorders, topical, nanoparticle.
Abstract: The topical application of therapeutic agent has shown promising efficacy in the treatment of skin disorders. The siRNA based therapies have been used for treatment of various disorders including skin diseases. The topical delivery of siRNA based therapies has opened new perspectives for the treatment of skin disorders. The use of siRNA is limited due to the rapid degradation and poor cellular uptake. Also, the stratum corneum, the top layer of skin is the major barrier for the delivery of topical agents. There is unmet need for efficient topical formulation that will deliver the siRNA to the site of action and also overcome the associated siRNA delivery limitations. The topical delivery of siRNA has been achieved using viral or nonviral methods, and the combination of non-viral methods with an active permeation method such as iontophoresis, sonophoresis or microneedles for the treatment of skin disorders. These delivery approaches have been tested in a preclinical setup and few cases the results have shown promise for clinical trials. This review provides an update on the advances in the non-viral delivery approaches for siRNA delivery for skin disorders and use of various delivery approaches for efficient delivery at the disease site.
Export Options
About this article
Cite this article as:
Aldawsari Mohammed, Chougule B. Mahavir and Babu Jayachandra R., Progress in Topical siRNA Delivery Approaches for Skin Disorders, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/1381612821666150911093606
DOI https://dx.doi.org/10.2174/1381612821666150911093606 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer
Current Pharmaceutical Design Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Current Cancer Drug Targets The Beneficial Effects of Sulfur-containing Amino Acids on Cisplatininduced Cardiotoxicity and Neurotoxicity in Rodents
Current Medicinal Chemistry Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date
Recent Patents on Biomarkers G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Medical Applications of Hyperthermia Based on Magnetic Nanoparticles
Recent Patents on Biomedical Engineering (Discontinued) Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Current Cancer Drug Targets Targeted Tumor Therapies at a Glance
Current Drug Targets A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Mapping the Technological Knowledge Landscape: The Case of Epigenetics
Recent Patents on Anti-Cancer Drug Discovery MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets